Industry insight from report on Glia...
? ADCON-P: The third ADCON product is for pelvic/gynecological surgeries. This is a huge market, more than triple (1.3 million US surgeries annually) the size of the market for ADCON-L. Considering its tiny (37 pt) size, the US pilot study of ADCON-P yielded outstanding results, : patients receiving ADCON-P had a 57% reduction in uterine adhesions, and the area of adhesions was reduced by 63%. The 200pt Phase III trial in laparoscopic surgery is now underway, completion of enrollment expected by year-end. Filing for marketing approval should occur the following quarter, around this time next year. ADCON-P will go up against Genzyme and Johnson and Johnson surgical film products already on the market, which are more difficult to utilize than ADCON-P. A far more promising competitor from Lifecore Biomedical (LCBM), called Intergel, whose clinical data appears strong and will likely be approved before ADCON-P (and marketed by Johnson & Johnson). Gliatech will not use the contract sales model for this marketing effort, the market is too large, the competition too organized. For ADCON-P (and eventually, ADCON-A, Gliatech is going to need a major marketing partner. In the world of surgical sales, with Johnson & Johnson committed to Lifecore Biomedical, a company like US Surgical might be a strategic fit. While this would reduce Gliatech's per-unit revenue share, it would make ADCON-P a player in a much larger arena. |
